Derivative of the tryptophan operon for expression of fused gene products
US4738921A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 27, 1984 |
| Grant date | Apr 19, 1988 |
| Priority date | — |
| Expiry date | Sep 27, 2004 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/26
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention comprises improved derivatives of the tryptophan operon useful for expressing fused gene products in E. coli and relate organism. Two of the improved derivatives disclosed are encoded on 0.43 and 0.55 kb EcoRI restriction fragments from plasmids pCZ20 and pLEBGH2 (in strains NRRL B-15881 and NRRL B-15882), respectively. The modified derivatives have been placed on recombinant DNA cloning and expression vectors. A variety of expression vectors have been constructed that drive expression of fused gene products. Two novel gene sequences, encoding insulin-like growth factors I and II, have been expressed with the modified tryptophan operon system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.